# ClinicalTrials.gov record NCT07481734

> PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct07481734-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07481734-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07481734-tesamorelin-v1.json
- Content SHA-256: `453faab58b626d896bd596e17ffe14a80b69925f3eefc44fbe500e31147e4e1a`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07481734 ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

## Sources

<a id="source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31"></a>
- **ClinicalTrials.gov record NCT07481734 · retained source version 2026-03-19:79e26d9bce317d5509d2c5e266b142d6817cbc5b738f52bccb7f92f89d1db2be** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07481734) (`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07481734." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07481734-tesamorelin-v1.json SHA-256: 453faab58b626d896bd596e17ffe14a80b69925f3eefc44fbe500e31147e4e1a.